The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 17, 1993
Filed:
Sep. 18, 1989
Thomas Gerstenberg, Frederiksberg, DK;
Jan Fahrenkrug, Hellerup, DK;
Bent Ottesen, Frederiksberg, DK;
Senetek, plc, St. Louis, MO (US);
Abstract
The present invention provides methods and compositions for inducing penile erections, sufficient for vaginal penetration, in a human male suffering from impotence. When the impotence is substantially only neurogenic, psycogenic or neurogenic and psychogenic, a method of the invention comprises (A) administering to the male by intracavernosal injection peptide N-terminal histidine C-terminal methionineamide and (B) sexually stimulating the male. When the impotence is caused by severe atherosclerosis, a method of the invention comprises (A) administering to the male by intracavernosal injection an amount of a physiologically acceptable composition comprising (1) a neuropeptide selected from the group consisting of human vasoactive intestinal peptide and peptide N-terminal histidine C-terminal methionineamide and (2) an alpha-adrenergic blocker, such as phentolamine or prazosin, and (B) sexually stimulating the male. The invention also entails a physiologically acceptable composition suitable for use in inducing, upon administration by intracavernosal injection, an erection, sufficient for vaginal penetration, in a human male suffering from impotence, which is caused by severe atherosclerosis, which composition comprises (1) a neuropeptide selected from the group consisting of vasoactive intestinal peptide and peptide N-terminal histidine C-terminal methionineamide and (2) an alpha-adrenergic blocker, such as phentolamine or prazosin.